Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors by Chee, J. et al.
Chee et al. BMC Res Notes          (2018) 11:864  
https://doi.org/10.1186/s13104-018-3953-x
RESEARCH NOTE
Tumour associated lymphocytes 
in the pleural effusions of patients 
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of inhibitory receptors
Jonathan Chee1* , Mark W. Watson2, Abha Chopra2, Bella Nguyen3, Alistair M. Cook1, Jenette Creaney1, 
Willem J. Lesterhuis1, Bruce W. Robinson1,4, Y. C. Gary Lee4,5, Anna K. Nowak1,3, Richard A. Lake1 
and Alison M. McDonnell1
Abstract 
Objective: Pleural effusion (PE) is a common feature of malignant pleural mesothelioma. These effusions typically 
contain lymphocytes and malignant cells. We postulated that the PE would be a source of lymphocytes for analysis of 
tumor immune milieu. The aim of this study was to compare the phenotype and T cell receptor usage of pleural effu-
sion T cells with paired concurrently drawn peripheral blood lymphocytes. We used multi-parameter flow cytometry 
and high-throughput T cell receptor sequencing to analyse peripheral blood and pleural effusion mononuclear cells.
Results: Both  CD8+ and  CD4+ T cells from effusion showed increased expression of T cell inhibitory receptors PD-1, 
LAG-3 and Tim-3 compared to blood. Comprehensive T cell receptor sequencing on one of the patients showed 
a discordant distribution of clonotypes in the antigen-experienced (PD-1+) compartment between effusion and 
blood, suggesting an enrichment of antigen specific clonotypes in the effusion, with potential as an immunological 
response biomarker.
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Introduction
Malignant mesothelioma originates from mesothelial 
cells lining the pleura. Most patients have a history of 
asbestos exposure, present with advanced disease and 
receive palliative chemotherapy only. The median sur-
vival for patients treated with cisplatin and pemetrexed 
is around 12 months [1] and most patients die from their 
disease.
The success of immunotherapy targeting checkpoint 
inhibitory T cell receptors in a variety of cancer types, 
has seen the anti-tumour immune response re-emerge as 
a promising prognostic marker, therapeutic target and a 
potential biomarker of response for cancer immunother-
apy [2]. Such therapies are under clinical investigation 
for the treatment of patients with mesothelioma [3], and 
understanding T cell responses in these patients is cru-
cial for improving the efficacy of immunotherapy.
The prognostic significance of tumour infiltrating lym-
phocytes (TILs) is established for many cancer types 
including mesothelioma [4]. Longitudinal characterisa-
tion of T cell phenotype and T cell receptor (TCR) usage 
at the tumour site could help us to understand how to 
promote effective anti-tumour immunity. However, 
serial analysis of immune changes at the tumour site is 
rarely feasible in clinical practice as tumour biopsies are 
invasive. Malignant pleural effusions (PE), a recurrent 
and common complication of mesothelioma, are regu-
larly drained as a palliative measure and can be sampled 
serially [5]. PE is an abnormal accumulation of fluid in 
Open Access
BMC Research Notes
*Correspondence:  jonathan.chee@uwa.edu.au 
1 National Centre for Asbestos Related Diseases, School of Medicine 
and Pharmacology, University of Western Australia, Nedlands, Western 
Australia, Australia
Full list of author information is available at the end of the article
Page 2 of 6Chee et al. BMC Res Notes          (2018) 11:864 
the pleural space with T lymphocytes the predominant 
immune cells [6]. Given that malignant PE are intimately 
associated with mesothelioma, they form an impor-
tant part of the local tumour environment and as such, 
immune events in the PE may serve as surrogate mark-
ers of the intratumoural milieu. We characterized T 
cell phenotype in PE and peripheral blood in 9 patients 
with mesothelioma, and compared the T cell repertoire 




This study was approved by the site Human Research 
Ethics Committee and the patient provided written 
informed consent for collection and analysis of bio-
logical samples. Blood was collected into a heparinized 
 Vacutainer® (BD Diagnostics) and peripheral blood mon-
onuclear cells (PBMC) isolated according to manufactur-
er’s instructions. A 50 ml PE sample was collected. Ficoll 
density centrifugation was used to isolate PE mononu-
clear cells (PEMC). Cells were stored in liquid nitrogen 
until analysis.
The nine participants in the current study had a histo-
logically or cytologically confirmed diagnosis of malig-
nant pleural mesothelioma. Participants could have any 
stage or duration of disease; prior treatment with chem-
otherapy or radiotherapy was allowed. Effusions from 
patients with prior talc pleurodesis or pleural infection 
were excluded from this study.
Flow cytometry
Thawed cells were labelled with antibodies: CD14-APC-
eFluor®780 (61D3), CD19-APC-eFluor®780 (HIB19), 
LAG-3-PE (3DS223H) (eBioscience); CD45-BUV395 
(HI30), CD3-BV510 (UCHT1), CD4-BV711 (OKT4), 
CD8a-FITC (RPA-T8), PD-1-PerCP-Cy5.5 (EH12.2H7), 
PD-1-PECy7 (EH12.2H7), Tim-3-APC (F38-232), 
CD45RA-BV785 (HI100) (BioLegend). Dead cells 
were excluded using Viability Dye eFluor™780 (Ther-
moFisher). Samples were acquired on a LSR Fortessa (BD 
Biosciences) and analyzed using FlowJov10 (Treestar).
TCR sequencing
Cells were sorted on CD3, CD4, CD8 and PD-1 expres-
sion with a BD Influx™ (BD Biosciences). DNA was 
extracted from sorted cells using QIAmp DNA Kit (Qia-
gen). DNA sequences were amplified with a Human 
TCRβ ImmunoSeq Kit (Adaptive Biotechnologies). 
Sequencing was performed on a MiSeq (MS-102-3001, 
Illumina) and data was analyzed using the Adaptive 
ImmunoSeq suite. Each TCR clonotype is defined as a 
unique TCRβ nucleotide sequence. Differential abun-
dance of T cell clones were compared as previously 
described [7]. The diversity of each sample was assigned 
a clonality score [8], whereby each score varied from 0 
(each clone appearing once) to 1 (monoclonal sample).
Results
Malignant effusions have proportionately more T cells 
that express inhibitory receptors, compared to blood
Pleural effusion mononuclear cells (PEMC) were con-
temporaneously collected with peripheral blood 
mononuclear cells (PBMC) from 9 male patients with 
pleural mesothelioma. Patient characteristics are shown 
in Table  1. Biological samples were analyzed by multi-
parameter flow cytometry. The  CD3+ T cell component 
of both PE and peripheral blood demonstrated similar 
proportions of the  CD8+ and  CD4+ subsets (blood vs. 
Table 1 Patient characteristics at the point when effusion and blood samples were taken
*Patient samples underwent T cell receptor sequencing






Histology Prior treatment Indwelling pleural 
catheter (IPC)/
thoracentesis
Effusion vol. (ml) Cell concentration 
in effusion 
(× 107/100 ml)
1 76 335 Epithelioid No IPC 1050 3.60
2 66 145 Epithelioid No Thoracentesis 535 8.47
3 80 403 Epithelioid Carboplatin/pem-
etrexed
Thoracentesis 200 3.02
4 61 705 Epithelioid No IPC 700 9.00
5 58 250 Epithelioid Cisplatin/pem-
etrexed
IPC 300 2.16
6 59 50 Epithelioid No Thoracentesis 950 3.90
7 76 14 Not specified No IPC 1450 2.21
8 68 68 Epithelioid No Thoracentesis 1080 2.22
*9 72 389 Not specified No IPC 120 2.99
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effusion,  CD4+ T cells: 71.9% ± 10.1% vs. 70.3% ± 12.5%; 
 CD8+ T cells: 22.2% ± 9.7% vs. 23.3% ± 9.6%).
T cells within the tumour environment can display a 
dysfunctional phenotype characterized by expression of 
T cell inhibitory receptors [9]. Therefore we compared 
the cell surface expression of PD-1, LAG-3 and Tim-3 on 
T cells in peripheral blood and PE. In the  CD4+ T cell 
population, there was a statistically significant larger pro-
portion of PE T cells that expressed PD-1 (p = 0.004), 
Tim-3 (p = 0.004) and LAG-3 (p = 0.004) compared to 
peripheral blood (Fig.  1a). The proportion of  CD8+ T 
cells expressing PD-1 (p = 0.004) and LAG-3 (p = 0.01) 
was also significantly higher in the PE compared with 
peripheral blood (Fig.  1a). Overall, the proportion of 
 CD4+ and  CD8+ T cells expressing PD-1 in PE was five-
fold higher than T cells in peripheral blood, with PD-1 
being the inhibitory receptor most overexpressed in PE 
T cell subsets compared with Tim-3  (CD4+ p = 0.004, 
 CD8+ p = 0.0001) and LAG-3  (CD4+ p = 0.002,  CD8+ 
p = 0.04) (Fig. 1b).
Malignant effusions have diverse TCR repertoires compared 
to blood
We examined the T cell repertoire by sequencing the 
TCRβ chain in T cells from PE and matched periph-
eral blood. As PD-1 was the most abundantly expressed 
T cell inhibitory receptor in our PE samples compared 
with blood, T cell subsets were further sorted into 
 CD4+PD-1+ and  CD8+PD-1+ populations. We per-
formed high throughput TCRseq in  CD4+,  CD4+PD-1+, 
 CD8+ and  CD8+PD-1+ T cells derived from matched 
PE and peripheral blood. This was performed in a sin-
gle participant (patient 9 in Table  1), who had no prior 
treatment that might alter the TCR repertoire, and was 
selected on the basis of sample availability.
CD4+ T cells in PE and PB demonstrated receptor 
diverse populations (Clonality < 0.02) (Fig.  2a).  CD8+ T 
cells in blood had a higher clonality score compared to 
the PE, suggesting expansion of specific TCR clonotypes 
in the blood (Fig. 2a). A single dominant TCR clone com-
prised 27.6% of total  CD8+ T cells in PB, but only 1.4% of 
effusion  CD8+ T cells. Both blood and PE contained dis-
tinct  CD8+ T cell clonotypes that differentially populated 
one compartment or the other (Fig. 2b). There were fewer 
differentially expressed  CD4+ clonotypes (Fig. 2c).
When we examined the PD-1+ subsets, the clonality 
scores in the blood were similarly higher than the effu-
sion (Fig.  2d). The number of differentially expressed 
 CD8+PD-1+ clones in each compartment were similar 
to the  CD8+ analysis (Fig.  2e). Interestingly, the highly 
dominant  CD8+ T cell clone in this patient’s blood was 
not present in the  CD8+PD-1+ PBMCs, suggesting this 
patient had an antecedent infection independent of the 
pleural space. Importantly, the number of differentially 
expressed  CD4+ T cell clones in each compartment 
was higher in the  CD4+PD-1+ analysis compared to the 
 CD4+ analysis (27 vs. 3; Fig. 2f ). There were marked clo-
notypic expansions in  CD4+PD-1+ population that were 
not evident in the bulk  CD4+ population, showing that 
some differences were only observed after fine analysis of 
clonal frequency associated with phenotype.
Discussion
Tumour biopsies from patients with mesothelioma are 
difficult to obtain, can cause significant morbidity, and 
are usually only taken once at diagnosis unless a sub-
sequent surgical resection is performed. Thus, serial 
collection of malignant PE provides a unique opportu-
nity to analyze dynamic events adjacent to the tumour 
microenvironment over time. A recent study by Aaerts 
et al. showed that the cellular composition of malignant 
PE over time is dynamic and influenced by response to 
treatment [10]. While this study was limited to a small 
group of patients, ongoing longitudinal studies will deter-
mine if PE T cells behave similarly to TILs and periph-
eral blood lymphocytes during disease progression and 
immunotherapy. Our data suggest that PE T cells, like 
TILs, exhibit an exhausted phenotype characterized by 
increased expression of inhibitory markers as compared 
with peripheral blood T cells. In line with this, previ-
ous studies have demonstrated increased expression of 
PD-1 and Tim-3 on  CD4+ and  CD8+ T cells in PE com-
pared with matched blood in patients with mesotheli-
oma [11, 12] and lung cancer [13–15], suggesting that T 
cells in the PE more closely approximate TILs than do T 
cells in peripheral blood. Of note, the expression of co-
inhibitory markers on TILs has been shown to correlate 
with response to immunotherapy [16], supporting the 
potential for PE T cells to provide predictive information 
longitudinally.
We examined the T cell repertoire from PE and blood 
in a single patient using TCRseq.  CD4+ and  CD8+ TCR 
repertoires were diverse in the PE, suggesting minimal 
T cell expansion in the PE of this patient. This contrasts 
oligoclonal T cell expansion observed in ascites derived 
from patients with ovarian cancer [17]. We observed a 
more restricted TCR repertoire in effusion  CD4+PD-1+ 
T cells compared to  CD4+ T cells, similar to previous 
studies studying PD-1+ TILs [9, 18]. In depth analysis of 
 CD4+PD-1+ T cells also uncovered more differentially 
expressed TCR clones in the effusion, suggesting that 
focusing on PD-1+ T cells might yield important insight 
into the immunological milieu.
PD-1+ T cells is a population of interest to under-
stand the relationship between T cells in the periph-
eral blood, PE and tumour. As we reported the findings 






Fig. 1 Frequency of inhibitory receptor expressing T cells in matched blood and effusion samples from malignant mesothelioma patients. a 
PD-1, Tim-3 and LAG-3 expressing  CD4+ (top row) and  CD8+ (bottom row) T cells plotted as a frequency of total  CD3+CD4+ or  CD3+CD8+ T cells 
respectively. Each point and connecting line represents a paired patient sample, and the star on each graph represents the single patient sample 
that underwent TCR sequencing. All paired samples were compared using a Wilcoxon’s test. b Frequency of PD-1, Tim-3 and LAG-3 expressing  CD4+ 
and  CD8+ T cells from effusion samples. Matched samples were compared with a Friedman test, corrected for multiple comparisons using Dunn’s 
test
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from a single patient, it remains to be seen if TCR rep-
ertoire in the PE is equally diverse in other patients 
with mesothelioma, or if the repertoire changes after 
different therapies. The specificity of T cells in the 
effusion is still to be determined, as is their ability to 
recognize tumour antigens.
Limitations
The study was limited by small patient numbers, espe-
cially with one patient for the TCR analysis. Tumour 
biopsies were unavailable for a comprehensive compari-
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Fig. 2 PE T cells consist of unique TCR clonotypes compared with peripheral blood. a Clonality score of bulk  CD4+ and  CD8+ populations in 
effusion and blood. b Scatter plot of the most frequent TCR clonotype abundance in PE versus PB,  CD8+ T cells. Red circles represent 45 individual 
TCR clonotypes that were present at significantly higher frequencies in the effusion than in the blood. Blue circles represent twenty clonotypes 
at higher frequencies in the blood than PE. c Scatter plot of the differential abundance of TCR clonotypes in PE versus PB,  CD4+ T cells. Ten clones 
present at higher frequencies in the blood, and three clones higher in PE. Dotted curve line represents threshold for statistical comparison. d 
Clonality score of PD-1+ T cells. e Scatter plot of differential abundance of TCR clonotypes in  CD8+PD-1+ T cell populations. Twenty-one clones 
at higher frequencies in blood, thirty-one clones higher in PE. f Differential abundance in  CD4+PD-1+ populations. Nineteen clones at higher 
frequencies in blood, twenty-seven clones higher in PE
Page 6 of 6Chee et al. BMC Res Notes          (2018) 11:864 
Authors’ contributions
JCh and AM performed experiments, wrote, and edited the main manuscript 
text. AM, ACo, JC, MW, ACh prepared figures. BN collected human samples. 
JC, WL, BR, YL provided intellectual input into manuscript. AN, RL and AM 
provided input into study design and experimental setup. All authors read and 
approved the final manuscript.
Author details
1 National Centre for Asbestos Related Diseases, School of Medicine and Phar-
macology, University of Western Australia, Nedlands, Western Australia, Aus-
tralia. 2 Institute for Immunology and Infectious Diseases, Murdoch University, 
Murdoch, Australia. 3 Department of Medical Oncology, Sir Charles Gairdner 
Hospital, Nedlands, Western Australia, Australia. 4 Department of Respiratory 
Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia. 
5 Institute of Respiratory Health, School of Medicine, University of Western 
Australia, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia. 
Acknowledgements
We acknowledge the facilities, and the scientific and technical assistance 
of the Australian Microscopy & Microanalysis Research Facility at the Centre 
for Microscopy, Characterisation & Analysis University of Western Australia, a 
facility funded by the University, State and Commonwealth Governments. The 
authors also acknowledge Justin Leon and Cynthia Gregory for sample collec-
tion and processing.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Availability of data and materials
The datasets used and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Ethics approval and consent to participate
This study was approved by the Sir Charles Gairdner Hospital Human Research 
Ethics Committee and the patient provided written informed consent for col-
lection and analysis of biological samples.
Funding
We acknowledge funding from Cancer Council Western Australia, Raine Foun-
dation, University of Western Australia, US Department of Defence, the Austral-
ian Science and Industry Endowment Fund, Insurance Commission of Western 
Australia and the National Health and Medical Research Council.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 29 October 2018   Accepted: 26 November 2018
References
 1. Kondola S, Manners D, Nowak AK. Malignant pleural mesothelioma: 
an update on diagnosis and treatment options. Ther Adv Respir Dis. 
2016;10(3):275–88.
 2. Lesterhuis WJ, Bosco A, Millward MJ, Small M, Nowak AK, Lake RA. 
Dynamic versus static biomarkers in cancer immune checkpoint block-
ade: unravelling complexity. Nat Rev Drug Discov. 2017;16:264–74.
 3. McDonnell AM, Cook A, Robinson BWS, Lake RA, Nowak AK. Serial 
immunomonitoring of cancer patients receiving combined antagonistic 
anti-CD40 and chemotherapy reveals consistent and cyclical modulation 
of T cell and dendritic cell parameters. BMC Cancer. 2017;17(1):417.
 4. Yamada N, Oizumi S, Kikuchi E, Shinagawa N, Konishi-Sakakibara J, 
Ishimine A, Aoe K, Gemba K, Kishimoto T, Torigoe T, et al.  CD8+ tumor-
infiltrating lymphocytes predict favorable prognosis in malignant 
pleural mesothelioma after resection. Cancer Immunol Immunother. 
2010;59(10):1543–9.
 5. West SD, Lee YC. Management of malignant pleural mesothelioma. Clin 
Chest Med. 2006;27(2):335–54.
 6. Scherpereel A, Grigoriu BD, Noppen M, Gey T, Chahine B, Baldacci S, 
Trauet J, Copin MC, Dessaint JP, Porte H, et al. Defect in recruiting effector 
memory  CD8+ T-cells in malignant pleural effusions compared to normal 
pleural fluid. BMC Cancer. 2013;13:324.
 7. DeWitt WS, Emerson RO, Lindau P, Vignali M, Snyder TM, Desmarais 
C, Sanders C, Utsugi H, Warren EH, McElrath J, et al. Dynamics of the 
cytotoxic T cell response to a model of acute viral infection. J Virol. 
2015;89(8):4517–26.
 8. Stewart JJ, Lee CY, Ibrahim S, Watts P, Shlomchik M, Weigert M, Litwin S. 
A Shannon entropy analysis of immunoglobulin and T cell receptor. Mol 
Immunol. 1997;34(15):1067–82.
 9. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon 
A, Farid S, Dudley ME, et al. PD-1 identifies the patient-specific CD8(+) 
tumor-reactive repertoire infiltrating human tumors. J Clin Investig. 
2014;124(5):2246–59.
 10. Lievense LA, Bezemer K, Cornelissen R, Kaijen-Lambers ME, Hegmans 
JP, Aerts JG. Precision immunotherapy; dynamics in the cellular profile 
of pleural effusions in malignant mesothelioma patients. Lung cancer. 
2016;107:36–40.
 11. Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, 
Orlandi A, Ferroni P, Schlom J, Guadagni F, et al. Malignant mesothelioma 
effusions are infiltrated by  CD3+ T cells highly expressing PD-L1 and the 
PD-L1+ tumor cells within these effusions are susceptible to ADCC by the 
anti-PD-L1 antibody avelumab. J Thorac Oncol. 2016;11(11):1993–2005.
 12. Marcq E, Waele J, Audenaerde JV, Lion E, Santermans E, Hens N, Pauwels 
P, van Meerbeeck JP, Smits ELJ. Abundant expression of TIM-3, LAG-3, 
PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of 
mesothelioma patients. Oncotarget. 2017;8(52):89722–35.
 13. Li L, Yang L, Wang L, Wang F, Zhang Z, Li J, Yue D, Chen X, Ping Y, Huang 
L, et al. Impaired T cell function in malignant pleural effusion is caused 
by TGF-beta derived predominantly from macrophages. Int J Cancer. 
2016;139(10):2261–9.
 14. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, 
Gandhi L, Redig AJ, Rodig SJ, Asahina H, et al. Adaptive resistance to 
therapeutic PD-1 blockade is associated with upregulation of alternative 
immune checkpoints. Nat Commun. 2016;7:10501.
 15. Hu CY, Zhang YH, Wang T, Chen L, Gong ZH, Wan YS, Li QJ, Li YS, Zhu 
B. Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant 
pleural effusion of lung cancer. Clin Exp Immunol. 2016;186(1):106–14.
 16. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, 
Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade 
induces responses by inhibiting adaptive immune resistance. Nature. 
2014;515(7528):568–71.
 17. Jang M, Yew PY, Hasegawa K, Ikeda Y, Fujiwara K, Fleming GF, Nakamura Y, 
Park JH. Characterization of T cell repertoire of blood, tumor, and ascites 
in ovarian cancer patients using next generation sequencing. Oncoim-
munology. 2015;4(11):e1030561.
 18. Pasetto A, Alena G, Robbins PF, Deniger DC, Prickett TD, Matus-Nic-
odemos R, Douek DC, Howie B, Robins H, Parkhurst MR, et al. Tumor- and 
neoantigen-reactive T-cell receptors can be identified based on their 
frequency in fresh tumor. Cancer Immunol Res. 2016;4:734–43.
